Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947976258> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2947976258 abstract "e14014 Background: The cancer-cell-killing property of Multiple Antigen Specific Cellular Therapy (MASCT) may be enhanced by blocking PD-1 in vitro and reversing vascular endothelial growth factor (VEGF)/VEGF receptor 2-mediated immunosuppression with apatinib. We analyzed pooled data from our phase Ⅰ/Ⅱ trials to assess the toxicity and efficacy of PD-1 blockade (SHR-1210)-activated MASCT (aMASCT) alone or in combination with apatinib in patients with advanced solid tumors. Methods: Patients with selected types of advanced solid tumors received aMASCT alone (n = 32) or aMASCT plus apatinib (500 mg q.d., n = 38) after standard treatment. The primary endpoint was the safety profile; antitumor response, progression-free survival (PFS), and overall survival (OS) were the secondary endpoints. Circulating regulatory T cells (Tregs) were quantified before and after aMASCT infusion. Results: Treatment-related adverse events (AEs) occurred in 18/32 (56.3%) and 25/38 (65.8%) patients in the aMASCT and aMASCT plus apatinib groups, respectively; fever and chills were the most frequently observed AEs. No serious AEs were reported, and apatinib did not increase immunotherapy-related toxicity. The objective response rate was improved with aMASCT plus apatinib group compared with aMASCT group (34.2% and 18.8%, respectively); PFS was longer (median, 6.0 and 4.5 months, respectively, P < 0.05), but OS was not improved (median, 10.0 and 8.2 months, respectively, P = 0.098). Multivariate analyses indicated that two or more cycles of aMASCT treatment was an independent favorable prognostic factor of PFS and OS. Circulating Tregs decreased in both groups after one cycle of aMASCT treatment (P < 0.05). Conclusions: Treatment with aMASCT plus apatinib was safe and effective in advanced solid tumors. Apatinib plus aMASCT may be beneficial for patients with advanced solid tumors. Clinical trial information: NCT02844881; NCT02858232." @default.
- W2947976258 created "2019-06-07" @default.
- W2947976258 creator A5008131882 @default.
- W2947976258 creator A5014392392 @default.
- W2947976258 creator A5068301710 @default.
- W2947976258 creator A5069618747 @default.
- W2947976258 date "2019-05-20" @default.
- W2947976258 modified "2023-09-26" @default.
- W2947976258 title "Safety and efficacy of PD-1 blockade-activated multiple antigen specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials." @default.
- W2947976258 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e14014" @default.
- W2947976258 hasPublicationYear "2019" @default.
- W2947976258 type Work @default.
- W2947976258 sameAs 2947976258 @default.
- W2947976258 citedByCount "1" @default.
- W2947976258 countsByYear W29479762582019 @default.
- W2947976258 crossrefType "journal-article" @default.
- W2947976258 hasAuthorship W2947976258A5008131882 @default.
- W2947976258 hasAuthorship W2947976258A5014392392 @default.
- W2947976258 hasAuthorship W2947976258A5068301710 @default.
- W2947976258 hasAuthorship W2947976258A5069618747 @default.
- W2947976258 hasConcept C121608353 @default.
- W2947976258 hasConcept C126322002 @default.
- W2947976258 hasConcept C143998085 @default.
- W2947976258 hasConcept C170493617 @default.
- W2947976258 hasConcept C2776694085 @default.
- W2947976258 hasConcept C2778468042 @default.
- W2947976258 hasConcept C2780668389 @default.
- W2947976258 hasConcept C2993640289 @default.
- W2947976258 hasConcept C535046627 @default.
- W2947976258 hasConcept C71924100 @default.
- W2947976258 hasConceptScore W2947976258C121608353 @default.
- W2947976258 hasConceptScore W2947976258C126322002 @default.
- W2947976258 hasConceptScore W2947976258C143998085 @default.
- W2947976258 hasConceptScore W2947976258C170493617 @default.
- W2947976258 hasConceptScore W2947976258C2776694085 @default.
- W2947976258 hasConceptScore W2947976258C2778468042 @default.
- W2947976258 hasConceptScore W2947976258C2780668389 @default.
- W2947976258 hasConceptScore W2947976258C2993640289 @default.
- W2947976258 hasConceptScore W2947976258C535046627 @default.
- W2947976258 hasConceptScore W2947976258C71924100 @default.
- W2947976258 hasLocation W29479762581 @default.
- W2947976258 hasOpenAccess W2947976258 @default.
- W2947976258 hasPrimaryLocation W29479762581 @default.
- W2947976258 hasRelatedWork W2347131556 @default.
- W2947976258 hasRelatedWork W2589863354 @default.
- W2947976258 hasRelatedWork W2735939614 @default.
- W2947976258 hasRelatedWork W2762667176 @default.
- W2947976258 hasRelatedWork W2798146525 @default.
- W2947976258 hasRelatedWork W2809064179 @default.
- W2947976258 hasRelatedWork W2809385373 @default.
- W2947976258 hasRelatedWork W287605918 @default.
- W2947976258 hasRelatedWork W2886213129 @default.
- W2947976258 hasRelatedWork W2890664813 @default.
- W2947976258 hasRelatedWork W2895515586 @default.
- W2947976258 hasRelatedWork W2900477772 @default.
- W2947976258 hasRelatedWork W2954288760 @default.
- W2947976258 hasRelatedWork W2982475566 @default.
- W2947976258 hasRelatedWork W2996192740 @default.
- W2947976258 hasRelatedWork W3034824835 @default.
- W2947976258 hasRelatedWork W3096739463 @default.
- W2947976258 hasRelatedWork W3105125497 @default.
- W2947976258 hasRelatedWork W3158107866 @default.
- W2947976258 hasRelatedWork W3175577386 @default.
- W2947976258 isParatext "false" @default.
- W2947976258 isRetracted "false" @default.
- W2947976258 magId "2947976258" @default.
- W2947976258 workType "article" @default.